SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.smaller Cos. Regulatory News (BSV)

Share Price Information for Br.smaller Cos. (BSV)

Share Price is delayed by 15 minutes
Get Live Data
73.50    0.50 (0.68%)
Bid:
72.00
Ask:
75.00
Spread: 3.00 (4.167%)
Market Cap: £306.68m
BSV Live PriceLast checked at - London Stock Exchange

Intraday Br.smaller Cos. Share Chart

3rd Quarter Results

19 Mar 2026 07:00

RNS Number : 2203X
British Smaller Companies VCT PLC
19 March 2026
 

British Smaller Companies VCT plc

Interim Management Statement for the quarter ended 31 December 2025

British Smaller Companies VCT plc (the "Company") presents its interim management statement for the quarter ended 31 December 2025. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

In the quarter to 31 December 2025 the Company's Total Return per share increased by 0.65 pence, a 0.8 per cent increase on the opening NAV per share. At 31 December 2025 the NAV per ordinary share totalled 78.70 pence, following payment of a 2.00 pence per share dividend in the quarter. 

Investment Activity

During the quarter, the Company invested £2.7 million into new investment TeamFeePay; and a further £4.1 million into existing portfolio companies Plandek, Xapien, Ohalo and Sipsynergy. Subsequent to the quarter end, the Company invested £3.0 million into existing portfolio company Summize. This takes the total amount invested so far this year to £18.5 million.

In October 2025, the Company realised its investment in Elucidat, receiving £5.5 million in initial proceeds, with additional deferred consideration of £0.7 million anticipated to be received over the next 18 months. To date, the Elucidat investment has generated a 1.3x return on the original cost of £4.3 million. Including deferred consideration, proceeds have the potential to rise to £6.2 million, and the return to 1.45x.

In December 2025, the Company realised its investment in SharpCloud, receiving £8.7 million in initial proceeds, with additional deferred consideration of £0.9 million anticipated to be received over the next two years. To date, the SharpCloud investment has generated a 2.0x return on the original cost of £4.3 million. Including deferred consideration, proceeds have the potential to rise to £9.6 million, and the return to 2.2x.

In December 2025, portfolio company Teraview successfully completed an oversubscribed listing on the Korean Stock Exchange. The Company subsequently realised 34 per cent of its holding prior to 31 December 2025, receiving proceeds of £1.2 million. The balance of the Company's holding was realised post-year end, in January 2026, generating a further £1.8 million of proceeds. Overall, the Teraview investment has generated an 8.1x return on the original cost of £0.4 million.

Post-year end, the Company realised its remaining holding in Vuealta, receiving proceeds of £0.7 million, in line with the valuation at the year end. Overall, the Vuealta investment has generated a 1.5x return on the original cost of £3.6 million.

The Company also realised its investment in Sipsynergy post-year end, with total expected proceeds of c. £0.9 million, in line with the valuation at the year end. This represents a 0.3x return on the original cost of £2.8 million.

 

Performance

The table below sets out movements in key metrics for the Company. 

 

 

30 September 2025

Net increase in Value

Shares issued

Dividends paid

Buyback of shares

Movement

In Period

31 December 2025

Net Assets (£m)

284.0

2.2

1.1

(7.1)

(1.7)

(5.5)

278.5

NAV per share (PPS)

80.05

0.65

-

(2.00)

-

(1.35)

78.70

Cumulative dividends paid (PPS)

186.15

-

-

2.00

-

2.00

188.15

Total Return (PPS)

266.20

0.65

-

-

-

0.65

266.85

Shares in issue

354,664,249

-

1,498,811

-

(2,231,911)

(733,100)

353,931,149

Cumulative dividends paid at 31 December 2025 were 188.15 pence per ordinary share (30 September 2025: 186.15 pence per ordinary share).

The movements in NAV and NAV per ordinary share are set out in the table below:

 

 

£m

Pence per

ordinary share

NAV at 30 September 2025

284.0

80.05

Increase in portfolio value

2.5

0.75

Net operating costs

(0.3)

(0.10)

2.2

0.65

Issue/buy-back of shares

(0.6)

-

Total Return in the period

1.6

0.65

NAV before dividends

285.6

80.70

Dividends paid

(7.1)

(2.00)

NAV at 31 December 2025

 

278.5

 

78.70

 

Dividends and shares in issue

On 19 December 2025 the Company issued 1,498,811 shares under the Company's Dividend Re-investment Scheme (DRIS).

Under its standing buyback authority, on 19 December 2025 the Company purchased 2,231,911 shares at 74.65 pence per share at a cost of £1.7 million. These shares are held in treasury. 

The first allotment of the Company's 2025/26 fundraise took place just after the period end, with £15.6 million of proceeds allotted on 7 January 2026. 19,484,289 shares were allotted, taking the total number of ordinary shares to 373,415,438, with a further 39,260,029 shares held in treasury.

Net assets

Net assets at 31 December 2025 comprised the following:

£000

% of net assets

Unquoted investments at fair value

160,361

57.6

Cash and money market funds

113,825

40.9

Other net assets

4,350

1.5

Net assets

278,536

100.0

Investments

The investment portfolio at 31 December 2025 comprised:

Valuation

£000

Cumulative valuation as a % of net assets

Matillion

19,618

7.0%

Unbiased

16,584

13.0%

Xapien

14,255

18.1%

Vypr

11,315

22.2%

Summize

9,973

25.8%

AutomatePro

9,760

29.3%

DrDoctor

6,276

31.5%

Workbuzz

5,961

33.7%

Plandek

5,902

35.8%

Force24

5,841

37.9%

105,485

37.9%

Other investments

54,876

57.6%

Total investments

160,361

57.6%

 

Portfolio performance

In the quarter to 31 December 2025, the aggregate portfolio valuation increased by £2.5 million. Several portfolio companies are demonstrating strong underlying growth of revenues, which has driven positive revaluation uplifts across several assets. 

Fundraising

The Company announced a new share offer on 25 September 2025, alongside British Smaller Companies VCT2 plc, with the intention of raising up to £85 million, in aggregate, which included an over-allotment facility of £25 million, in aggregate. The offers closed to new Applications on 18 December 2025. Gross Applications of £85 million have been received, of which c.£53 million relate to the Company. The first allotment of £25 million (£15.6 million relating to the Company) took place on 7 January 2026; the second and final allotment will take place between 1 and 2 April 2026.

Outlook

The portfolio continues to develop, with several holdings delivering strong growth during the period. Our active portfolio management approach allows us to stay close to investee companies and support them as they scale. Adding new companies to the portfolio and providing follow-on capital to support their growth remains central to our strategy.

The start of 2026 has seen further macroeconomic volatility, with the conflict in the Middle East adding to a challenging environment. There has also been a more cautious market view of software businesses, which has the potential to weigh on the valuations of portfolio companies in the near term; nonetheless, the portfolio continues to be positioned to benefit from an increasingly AI-led world. This, alongside the Company's strong liquidity position leaves it well-placed to manage downside risks, as well as deploy funds from its recent capital raise into promising new opportunities across the UK. 

We are grateful to shareholders for their continued support.

18 March 2026

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

For further information please contact:

Marcus Karia YFM Equity Partners Tel: 0113 244 1000

Alex Collins Panmure Liberum Tel: 0207 886 2767

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
QRTEAEDPFEDKEAA
Date   Source Headline
11th Jun 202612:15 pmRNSAnnual Financial Report
20th Apr 202610:00 amRNSAdmission to Trading
1st Apr 20269:00 amRNSIssue of Equity
27th Mar 20264:10 pmRNSTransaction in Own Shares
23rd Mar 202610:45 amRNSPublication of a Supplementary Prospectus
19th Mar 20267:00 amRNS3rd Quarter Results
30th Jan 20267:00 amRNSAdmission of Further Securities to Trading
7th Jan 20269:30 amRNSIssue of Equity
23rd Dec 20258:54 amRNSAmendments to AIFM Agreements
23rd Dec 20258:54 amRNSAmendments to AIFM Agreements
22nd Dec 20259:13 amRNSTransaction in Own Shares
22nd Dec 20259:13 amRNSTransaction in Own Shares
19th Dec 202510:02 amRNSPayment of Dividend and Issue of Equity
19th Dec 202510:02 amRNSPayment of Dividend and Issue of Equity
18th Dec 202512:14 pmRNSClose of Offers to new Applications
18th Dec 202512:14 pmRNSClose of Offers to new Applications
28th Nov 202510:00 amRNSHalf-year Financial Report
20th Nov 20259:00 amRNSOffer Update
11th Nov 20257:00 amRNSDividend Declaration
27th Oct 202511:00 amRNSNominal Capital Reduction
10th Oct 20253:41 pmRNSOffer Update
2nd Oct 20259:00 amRNSOffer Update
25th Sep 20259:04 amRNSPublication of a Prospectus
23rd Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 20257:00 amRNSInterim Management Statement
9th Sep 202512:56 pmRNSResult of AGM
22nd Aug 202510:45 amRNSNew combined offer for subscription
25th Jul 202510:16 amRNSPayment of dividend and issue of Equity
24th Jun 20257:00 amRNSTransaction in Own Shares
13th Jun 20251:30 pmRNSAnnual Financial Report
1st Apr 20258:02 amRNSDirector/PDMR Shareholding
1st Apr 20258:00 amRNSIssue of Equity
26th Mar 20255:13 pmRNSTransaction in Own Shares
24th Mar 202512:45 pmRNSPublication of Supplementary Prospectus
24th Mar 202512:45 pmRNSPublication of Supplementary Prospectus
18th Mar 20251:00 pmRNS3rd Quarter Results
30th Jan 20259:05 amRNSDirector/PDMR Shareholding
30th Jan 20259:00 amRNSIssue of Equity
27th Jan 20259:23 amRNSPayment of dividend and issue of shares
8th Jan 20252:14 pmRNSClose of Offer to new Applications
8th Jan 20252:13 pmRNSClose of Offer to new Applications
20th Dec 20249:26 amRNSPayment of dividend and issue of equity
17th Dec 20247:00 amRNSDividend Declaration
16th Dec 20245:09 pmRNSTransaction in Own Shares
29th Nov 20249:00 amRNSHalf-year Report
20th Nov 20241:00 pmRNSOffer Update
20th Nov 20241:00 pmRNSOffer Update
14th Nov 20247:48 amRNSDividend Declaration
1st Nov 20247:00 amRNSOffer Update
1st Nov 20247:00 amRNSOffer Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.